1. Home
  2. IKT vs VTGN Comparison

IKT vs VTGN Comparison

Compare IKT & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.50

Market Cap

111.8M

Sector

Health Care

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$4.33

Market Cap

122.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IKT
VTGN
Founded
2008
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
111.8M
122.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
IKT
VTGN
Price
$1.50
$4.33
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
354.4K
869.3K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$721,000.00
Revenue This Year
N/A
$54.26
Revenue Next Year
N/A
$478.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.33
$1.90
52 Week High
$4.20
$5.14

Technical Indicators

Market Signals
Indicator
IKT
VTGN
Relative Strength Index (RSI) 46.90 51.99
Support Level $1.40 $3.36
Resistance Level $1.61 $4.97
Average True Range (ATR) 0.11 0.51
MACD -0.01 -0.05
Stochastic Oscillator 38.46 54.49

Price Performance

Historical Comparison
IKT
VTGN

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Share on Social Networks: